-
1
-
-
0032569831
-
Tamoxifen in the treatment of breast cancer
-
10.1056/NEJM199811263392207 9828250 1:CAS:528:DyaK1cXnvFOitLs%3D
-
Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609-18. doi: 10.1056/NEJM199811263392207.
-
(1998)
N Engl J Med
, vol.339
, Issue.22
, pp. 1609-1618
-
-
Osborne, C.K.1
-
2
-
-
79952041937
-
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial
-
10.1016/S1470-2045(11)70033-X 21354370 1:CAS:528:DC%2BC3MXjs1Cgur4%3D
-
Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X.
-
(2011)
Lancet Oncol
, vol.12
, Issue.3
, pp. 236-244
-
-
Gianni, L.1
Dafni, U.2
Gelber, R.D.3
Azambuja, E.4
Muehlbauer, S.5
Goldhirsch, A.6
-
3
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
10.1056/NEJMoa052306 16236737 1:CAS:528:DC%2BD2MXhtFansr3L
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72. doi: 10.1056/NEJMoa052306.
-
(2005)
N Engl J Med
, vol.353
, Issue.16
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
-
4
-
-
43249123378
-
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics
-
10.1371/journal.pgen.1000054 18437204
-
Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008;4(4):e1000054. doi: 10.1371/journal.pgen.1000054.
-
(2008)
PLoS Genet
, vol.4
, Issue.4
, pp. 1000054
-
-
Garcia-Closas, M.1
Hall, P.2
Nevanlinna, H.3
Pooley, K.4
Morrison, J.5
Richesson, D.A.6
-
5
-
-
57149139395
-
Regulation of breast cancer metastasis by IGF signaling
-
10.1007/s10911-008-9105-5 19030970
-
Sachdev D. Regulation of breast cancer metastasis by IGF signaling. J Mammary Gland Biol Neoplasia. 2008;13(4):431-41. doi: 10.1007/s10911-008-9105-5.
-
(2008)
J Mammary Gland Biol Neoplasia
, vol.13
, Issue.4
, pp. 431-441
-
-
Sachdev, D.1
-
6
-
-
56749184290
-
Insulin and insulin-like growth factor signalling in neoplasia
-
10.1038/nrc2536 19029956 1:CAS:528:DC%2BD1cXhsVWhu7rL
-
Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-28. doi: 10.1038/nrc2536.
-
(2008)
Nat Rev Cancer
, vol.8
, Issue.12
, pp. 915-928
-
-
Pollak, M.1
-
7
-
-
0028293446
-
Expression and function of the insulin-like growth factor i system in human non-small-cell lung cancer and normal lung cell lines
-
7509779 1:CAS:528:DyaK2cXktlait7c%3D
-
Favoni RE, de Cupis A, Ravera F, Cantoni C, Pirani P, Ardizzoni A, et al. Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer. 1994;56(6):858-66.
-
(1994)
Int J Cancer
, vol.56
, Issue.6
, pp. 858-866
-
-
Favoni, R.E.1
De Cupis, A.2
Ravera, F.3
Cantoni, C.4
Pirani, P.5
Ardizzoni, A.6
-
8
-
-
0024460381
-
Blockade of the type i somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
-
10.1172/JCI114315 2553774 1:CAS:528:DyaL1MXmt1Kjs78%3D
-
Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull Jr FC, Allred DC, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989;84(5):1418-23. doi: 10.1172/JCI114315.
-
(1989)
J Clin Invest
, vol.84
, Issue.5
, pp. 1418-1423
-
-
Arteaga, C.L.1
Kitten, L.J.2
Coronado, E.B.3
Jacobs, S.4
Kull, Jr.F.C.5
Allred, D.C.6
-
9
-
-
0025189619
-
Overexpression of the human insulinlike growth factor i receptor promotes ligand-dependent neoplastic transformation
-
2153917 1:CAS:528:DyaK3cXhtFaktbg%3D
-
Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol. 1990;10(2):464-73.
-
(1990)
Mol Cell Biol
, vol.10
, Issue.2
, pp. 464-473
-
-
Kaleko, M.1
Rutter, W.J.2
Miller, A.D.3
-
10
-
-
34147193818
-
Constitutively active type i insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail
-
10.1128/MCB.01315-06 17296734 1:CAS:528:DC%2BD2sXkt1OgtbY%3D
-
Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail. Mol Cell Biol. 2007;27(8):3165-75. doi: 10.1128/MCB.01315-06.
-
(2007)
Mol Cell Biol
, vol.27
, Issue.8
, pp. 3165-3175
-
-
Kim, H.J.1
Litzenburger, B.C.2
Cui, X.3
Delgado, D.A.4
Grabiner, B.C.5
Lin, X.6
-
11
-
-
1042301373
-
A dominant negative type i insulin-like growth factor receptor inhibits metastasis of human cancer cells
-
10.1074/jbc.M305403200 14615489 1:CAS:528:DC%2BD2cXpslSitw%3D%3D
-
Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem. 2004;279(6):5017-24. doi: 10.1074/jbc.M305403200.
-
(2004)
J Biol Chem
, vol.279
, Issue.6
, pp. 5017-5024
-
-
Sachdev, D.1
Hartell, J.S.2
Lee, A.V.3
Zhang, X.4
Yee, D.5
-
12
-
-
0037308651
-
A chimeric humanized single-chain antibody against the type i insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I
-
12566306 1:CAS:528:DC%2BD3sXosVyisw%3D%3D
-
Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 2003;63(3):627-35.
-
(2003)
Cancer Res
, vol.63
, Issue.3
, pp. 627-635
-
-
Sachdev, D.1
Li, S.L.2
Hartell, J.S.3
Fujita-Yamaguchi, Y.4
Miller, J.S.5
Yee, D.6
-
13
-
-
9144234724
-
A fully human monoclonal antibody to the insulin-like growth factor i receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo
-
14695208 1:CAS:528:DC%2BD3sXhtVSqtbvL
-
Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003;63(24):8912-21.
-
(2003)
Cancer Res
, vol.63
, Issue.24
, pp. 8912-8921
-
-
Burtrum, D.1
Zhu, Z.2
Lu, D.3
Anderson, D.M.4
Prewett, M.5
Pereira, D.S.6
-
14
-
-
0024408247
-
Growth inhibition of human breast cancer cells in vitro with an antibody against the type i somatomedin receptor
-
2553250 1:CAS:528:DyaK3cXlsV2i
-
Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989;49(22):6237-41.
-
(1989)
Cancer Res
, vol.49
, Issue.22
, pp. 6237-6241
-
-
Arteaga, C.L.1
Osborne, C.K.2
-
15
-
-
0035863411
-
AKT activation up-regulates insulin-like growth factor i receptor expression and promotes invasiveness of human pancreatic cancer cells
-
11212254 1:CAS:528:DC%2BD3MXht1GmsLk%3D
-
Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001;61(2):589-93.
-
(2001)
Cancer Res
, vol.61
, Issue.2
, pp. 589-593
-
-
Tanno, S.1
Mitsuuchi, Y.2
Altomare, D.A.3
Xiao, G.H.4
Testa, J.R.5
-
16
-
-
27744465418
-
The IGF-I/IGF-I receptor pathway: Implications in the pathophysiology of thyroid cancer
-
16305477 1:CAS:528:DC%2BD2MXht1ShsrvL
-
Ciampolillo A, De Tullio C, Giorgino F. The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem. 2005;12(24):2881-91.
-
(2005)
Curr Med Chem
, vol.12
, Issue.24
, pp. 2881-2891
-
-
Ciampolillo, A.1
De Tullio, C.2
Giorgino, F.3
-
17
-
-
0032932822
-
Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells
-
10207053 1:CAS:528:DyaK1MXislSltLk%3D
-
Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19(5):3278-88.
-
(1999)
Mol Cell Biol
, vol.19
, Issue.5
, pp. 3278-3288
-
-
Frasca, F.1
Pandini, G.2
Scalia, P.3
Sciacca, L.4
Mineo, R.5
Costantino, A.6
-
18
-
-
70849120946
-
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease
-
19752219 1:CAS:528:DC%2BD1MXhsVyhsrbK
-
Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30(6):586-623.
-
(2009)
Endocr Rev
, vol.30
, Issue.6
, pp. 586-623
-
-
Belfiore, A.1
Frasca, F.2
Pandini, G.3
Sciacca, L.4
Vigneri, R.5
-
19
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
10.1016/j.cell.2011.02.013 21376230 1:CAS:528:DC%2BC3MXjsFeqtrk%3D
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
-
(2011)
Cell
, vol.144
, Issue.5
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
20
-
-
84863576934
-
A novel role for insulin resistance in the connection between obesity and postmenopausal breast cancer
-
10.3892/ijo.2012.1480 22614942 1:CAS:528:DC%2BC38Xht1WltLrM
-
Weichhaus M, Broom J, Wahle K, Bermano G. A novel role for insulin resistance in the connection between obesity and postmenopausal breast cancer. Int J Oncol. 2012;41(2):745-52. doi: 10.3892/ijo.2012.1480.
-
(2012)
Int J Oncol
, vol.41
, Issue.2
, pp. 745-752
-
-
Weichhaus, M.1
Broom, J.2
Wahle, K.3
Bermano, G.4
-
21
-
-
77953589054
-
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase
-
10.1677/ERC-09-0252 1:CAS:528:DC%2BC3cXptV2lsr8%3D
-
Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Canc. 2010;17(2):351-60. doi: 10.1677/ERC-09-0252.
-
(2010)
Endocr Relat Canc
, vol.17
, Issue.2
, pp. 351-360
-
-
Algire, C.1
Amrein, L.2
Zakikhani, M.3
Panasci, L.4
Pollak, M.5
-
22
-
-
58549084793
-
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women
-
10.1093/jnci/djn415 1:CAS:528:DC%2BD1MXltFSltw%3D%3D
-
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Canc Inst. 2009;101(1):48-60. doi: 10.1093/jnci/djn415.
-
(2009)
J Natl Canc Inst
, vol.101
, Issue.1
, pp. 48-60
-
-
Gunter, M.J.1
Hoover, D.R.2
Yu, H.3
Wassertheil-Smoller, S.4
Rohan, T.E.5
Manson, J.E.6
-
23
-
-
84855426420
-
Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes
-
10.1186/bcr3089 1:CAS:528:DC%2BC38Xjs1egs78%3D
-
Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast canc res: BCR. 2012;14(1):R8. doi: 10.1186/bcr3089.
-
(2012)
Breast Canc Res: BCR
, vol.14
, Issue.1
, pp. 8
-
-
Ferguson, R.D.1
Novosyadlyy, R.2
Fierz, Y.3
Alikhani, N.4
Sun, H.5
Yakar, S.6
-
24
-
-
79951938474
-
Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans
-
10.1126/scitranslmed.3001845 21325617
-
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13. doi: 10.1126/scitranslmed.3001845.
-
(2011)
Sci Transl Med
, vol.3
, Issue.70
-
-
Guevara-Aguirre, J.1
Balasubramanian, P.2
Guevara-Aguirre, M.3
Wei, M.4
Madia, F.5
Cheng, C.W.6
-
25
-
-
10744228607
-
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma
-
14633721 1:CAS:528:DC%2BD3sXptFOltL4%3D
-
Szereday Z, Schally AV, Varga JL, Kanashiro CA, Hebert F, Armatis P, et al. Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res. 2003;63(22):7913-9.
-
(2003)
Cancer Res
, vol.63
, Issue.22
, pp. 7913-7919
-
-
Szereday, Z.1
Schally, A.V.2
Varga, J.L.3
Kanashiro, C.A.4
Hebert, F.5
Armatis, P.6
-
26
-
-
33847392443
-
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: Implications for cancer therapy
-
10.1158/1078-0432.CCR-06-1910 17289896 1:CAS:528:DC%2BD2sXhsVyku7k%3D
-
Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res. 2007;13(3):1000-9. doi: 10.1158/1078-0432.CCR-06-1910.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.3
, pp. 1000-1009
-
-
Yin, D.1
Vreeland, F.2
Schaaf, L.J.3
Millham, R.4
Duncan, B.A.5
Sharma, A.6
-
27
-
-
79551547098
-
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth
-
10.1158/0008-5472.CAN-10-2274 21245093 1:CAS:528:DC%2BC3MXhsVCju7Y%3D
-
Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, et al. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res. 2011;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274.
-
(2011)
Cancer Res
, vol.71
, Issue.3
, pp. 1029-1040
-
-
Gao, J.1
Chesebrough, J.W.2
Cartlidge, S.A.3
Ricketts, S.A.4
Incognito, L.5
Veldman-Jones, M.6
-
28
-
-
84875741528
-
BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking rapamacyin-induced AKT activation
-
Chicago: J Clin Oncol abstr 3092
-
Adam PJ, Friedbichler K, Hofmann MH, Bogenrieder T, Borges E, Adolf GR. BI 836845, a fully human IGF ligand neutralizing antibody, to improve the efficacy of rapamycin by blocking rapamacyin-induced AKT activation. ASCO Annual Meeting, Chicago: J Clin Oncol; 2012. p. suppl; abstr 3092.
-
(2012)
ASCO Annual Meeting
, Issue.SUPPL.
-
-
Adam, P.J.1
Friedbichler, K.2
Hofmann, M.H.3
Bogenrieder, T.4
Borges, E.5
Adolf, G.R.6
-
29
-
-
68549126809
-
Unraveling insulin-like growth factor binding protein-3 actions in human disease
-
10.1210/er.2008-0028 19477944 1:CAS:528:DC%2BD1MXhtFaisbnN
-
Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30(5):417-37. doi: 10.1210/er.2008-0028.
-
(2009)
Endocr Rev
, vol.30
, Issue.5
, pp. 417-437
-
-
Jogie-Brahim, S.1
Feldman, D.2
Oh, Y.3
-
30
-
-
53249138207
-
Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models
-
10.1016/j.ghir.2008.04.002 18502161 1:CAS:528:DC%2BD1cXht1ejurrM
-
Alami N, Page V, Yu Q, Jerome L, Paterson J, Shiry L, et al. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res. 2008;18(6):487-96. doi: 10.1016/j.ghir.2008.04.002.
-
(2008)
Growth Horm IGF Res
, vol.18
, Issue.6
, pp. 487-496
-
-
Alami, N.1
Page, V.2
Yu, Q.3
Jerome, L.4
Paterson, J.5
Shiry, L.6
-
31
-
-
33746867442
-
Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo
-
16849573 1:CAS:528:DC%2BD28XmvFGktb0%3D
-
Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 2006;66(14):7245-52.
-
(2006)
Cancer Res
, vol.66
, Issue.14
, pp. 7245-7252
-
-
Jerome, L.1
Alami, N.2
Belanger, S.3
Page, V.4
Yu, Q.5
Paterson, J.6
-
32
-
-
0025066641
-
Elevated insulin receptor content in human breast cancer
-
10.1172/JCI114868 2243127 1:STN:280:DyaK3M%2Fls1Wmsg%3D%3D
-
Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990;86(5):1503-10. doi: 10.1172/JCI114868.
-
(1990)
J Clin Invest
, vol.86
, Issue.5
, pp. 1503-1510
-
-
Papa, V.1
Pezzino, V.2
Costantino, A.3
Belfiore, A.4
Giuffrida, D.5
Frittitta, L.6
-
33
-
-
0030679620
-
Insulin receptor expression and clinical outcome in node-negative breast cancer
-
9394418 1:CAS:528:DyaK2sXns1Omu7Y%3D
-
Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Phys. 1997;109(6):565-71.
-
(1997)
Proc Assoc Am Phys
, vol.109
, Issue.6
, pp. 565-571
-
-
Mathieu, M.C.1
Clark, G.M.2
Allred, D.C.3
Goldfine, I.D.4
Vigneri, R.5
-
34
-
-
35348815620
-
Phase i dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
-
10.1158/1078-0432.CCR-07-1118 17908976 1:CAS:528:DC%2BD2sXhtFSntLrE
-
Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13(19):5834-40. doi: 10.1158/1078-0432.CCR-07-1118.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.19
, pp. 5834-5840
-
-
Haluska, P.1
Shaw, H.M.2
Batzel, G.N.3
Yin, D.4
Molina, J.R.5
Molife, L.R.6
-
35
-
-
65549161522
-
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma
-
19258511 1:CAS:528:DC%2BD1MXjtFyqur4%3D
-
Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009;69(6):2443-52.
-
(2009)
Cancer Res
, vol.69
, Issue.6
, pp. 2443-2452
-
-
Avnet, S.1
Sciacca, L.2
Salerno, M.3
Gancitano, G.4
Cassarino, M.F.5
Longhi, A.6
-
36
-
-
34248170187
-
Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors
-
10.1016/j.ejca.2007.03.009 17451939 1:CAS:528:DC%2BD2sXlt1ahtr0%3D
-
Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer. 2007;43(8):1318-27. doi: 10.1016/j.ejca.2007.03.009.
-
(2007)
Eur J Cancer
, vol.43
, Issue.8
, pp. 1318-1327
-
-
Pandini, G.1
Wurch, T.2
Akla, B.3
Corvaia, N.4
Belfiore, A.5
Goetsch, L.6
-
37
-
-
33846807433
-
Disrupting insulin-like growth factor signaling as a potential cancer therapy
-
10.1158/1535-7163.MCT-06-0080 17237261 1:CAS:528:DC%2BD2sXmsVantg%3D%3D
-
Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6(1):1-12. doi: 10.1158/1535-7163.MCT-06-0080.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.1
, pp. 1-12
-
-
Sachdev, D.1
Yee, D.2
-
38
-
-
84863899215
-
Figitumumab plus exemestane versus exemestane as first-line treatment of postmenopausal hormone receptor-positive advanced breast cancer: A randomized, open-label phase II trial
-
Abs nr P1-17-01
-
Ryan PD, Neven P, Blackwell KL, Dirix LY, Barrios CH, Miller JWH et al. Figitumumab plus exemestane versus exemestane as first-line treatment of postmenopausal hormone receptor-positive advanced breast cancer: a randomized, open-label phase II trial. Cancer Res. 2011;71(24 Suppl.):239 s, Abs nr P1-17-01.
-
(2011)
Cancer Res.
, vol.71
, Issue.24 SUPPL.
, pp. 239
-
-
Ryan, P.D.1
Neven, P.2
Blackwell, K.L.3
Dirix, L.Y.4
Barrios, C.H.5
Miller, J.W.H.6
-
39
-
-
65249162840
-
Sequencing of type i insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo
-
10.1158/1078-0432.CCR-08-1401 19351773 1:CAS:528:DC%2BD1MXksV2ntrg%3D
-
Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res. 2009;15(8):2840-9. doi: 10.1158/1078-0432.CCR-08-1401.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.8
, pp. 2840-2849
-
-
Zeng, X.1
Sachdev, D.2
Zhang, H.3
Gaillard-Kelly, M.4
Yee, D.5
-
40
-
-
74449085460
-
The type i insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival
-
10.1038/onc.2009.316 19838209 1:CAS:528:DC%2BD1MXht1Ogsr%2FL
-
Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene. 2010;29(2):251-62. doi: 10.1038/onc.2009.316.
-
(2010)
Oncogene
, vol.29
, Issue.2
, pp. 251-262
-
-
Sachdev, D.1
Zhang, X.2
Matise, I.3
Gaillard-Kelly, M.4
Yee, D.5
-
41
-
-
80053525113
-
A phase i pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
-
10.1158/1078-0432.CCR-10-3336 21810918 1:CAS:528:DC%2BC3MXht1Ggs7bM
-
Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, et al. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011;17(19):6304-12. doi: 10.1158/1078-0432.CCR-10-3336.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.19
, pp. 6304-6312
-
-
Atzori, F.1
Tabernero, J.2
Cervantes, A.3
Prudkin, L.4
Andreu, J.5
Rodriguez-Braun, E.6
-
42
-
-
84863584930
-
Acquired resistance to tamoxifen is associated with loss of the type i insulin-like growth factor receptor (IGF1R): Implications for breast cancer treatment
-
doi: 10.1158/0008-5472.CAN-12-0684
-
Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor (IGF1R): implications for breast cancer treatment. Cancer Res. 2012. doi: 10.1158/0008-5472.CAN-12-0684.
-
(2012)
Cancer Res.
-
-
Fagan, D.H.1
Uselman, R.R.2
Sachdev, D.3
Yee, D.4
-
43
-
-
84857640868
-
The insulin and insulin-like growth factor receptor family in neoplasia: An update
-
10.1038/nrc3215 22337149 1:CAS:528:DC%2BC38Xit12jsrs%3D
-
Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-69. doi: 10.1038/nrc3215.
-
(2012)
Nat Rev Cancer
, vol.12
, Issue.3
, pp. 159-169
-
-
Pollak, M.1
-
44
-
-
80052143150
-
Insulin receptor and cancer
-
10.1530/ERC-11-0074 1:CAS:528:DC%2BC3MXhtlShsb%2FK
-
Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Canc. 2011;18(4):R125-47. doi: 10.1530/ERC-11-0074.
-
(2011)
Endocr Relat Canc
, vol.18
, Issue.4
, pp. 125-147
-
-
Belfiore, A.1
Malaguarnera, R.2
-
45
-
-
84861464145
-
Risk factors for breast cancer and expression of insulin-like growth factor-2 (IGF-2) in women with breast cancer in Wuhan City, China
-
10.1371/journal.pone.0036497 22662119 1:CAS:528:DC%2BC38Xot1GjsLw%3D
-
Qiu J, Yang R, Rao Y, Du Y, Kalembo FW. Risk factors for breast cancer and expression of insulin-like growth factor-2 (IGF-2) in women with breast cancer in Wuhan City, China. PLoS One. 2012;7(5):e36497. doi: 10.1371/journal.pone.0036497.
-
(2012)
PLoS One
, vol.7
, Issue.5
, pp. 36497
-
-
Qiu, J.1
Yang, R.2
Rao, Y.3
Du, Y.4
Kalembo, F.W.5
-
46
-
-
0028130305
-
Disproportionate growth in mice with Igf-2 transgenes
-
7524092 1:CAS:528:DyaK2cXmslyjsro%3D
-
Ward A, Bates P, Fisher R, Richardson L, Graham CF. Disproportionate growth in mice with Igf-2 transgenes. Proc Natl Acad Sci U S A. 1994;91(22):10365-9.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, Issue.22
, pp. 10365-10369
-
-
Ward, A.1
Bates, P.2
Fisher, R.3
Richardson, L.4
Graham, C.F.5
-
47
-
-
12144290914
-
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
-
1:CAS:528:DC%2BD2cXjtVartbg%3D
-
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Canc Cell. 2004;5(3):221-30.
-
(2004)
Canc Cell
, vol.5
, Issue.3
, pp. 221-230
-
-
Mitsiades, C.S.1
Mitsiades, N.S.2
McMullan, C.J.3
Poulaki, V.4
Shringarpure, R.5
Akiyama, M.6
-
48
-
-
12144285705
-
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase
-
1:CAS:528:DC%2BD2cXjtVartbk%3D
-
Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Canc Cell. 2004;5(3):231-9.
-
(2004)
Canc Cell
, vol.5
, Issue.3
, pp. 231-239
-
-
Garcia-Echeverria, C.1
Pearson, M.A.2
Marti, A.3
Meyer, T.4
Mestan, J.5
Zimmermann, J.6
-
49
-
-
73149120253
-
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
-
10.1158/1535-7163.MCT-09-0499 19996272 1:CAS:528:DC%2BD1MXhsFCitb3F
-
Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther. 2009;8(12):3341-9. doi: 10.1158/1535-7163.MCT-09-0499.
-
(2009)
Mol Cancer Ther
, vol.8
, Issue.12
, pp. 3341-3349
-
-
Carboni, J.M.1
Wittman, M.2
Yang, Z.3
Lee, F.4
Greer, A.5
Hurlburt, W.6
-
50
-
-
84255192030
-
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer
-
10.1158/0008-5472.CAN-11-1080 22042792 1:CAS:528:DC%2BC3MXhs1agtrvP
-
Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011;71(24):7597-607. doi: 10.1158/0008-5472.CAN-11-1080.
-
(2011)
Cancer Res
, vol.71
, Issue.24
, pp. 7597-7607
-
-
Hou, X.1
Huang, F.2
Macedo, L.F.3
Harrington, S.C.4
Reeves, K.A.5
Greer, A.6
-
51
-
-
84855313443
-
Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model
-
10.1371/journal.pone.0029213 22235273 1:CAS:528:DC%2BC38XotFWhsg%3D%3D
-
Durfort T, Tkach M, Meschaninova MI, Rivas MA, Elizalde PV, Venyaminova AG, et al. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. PLoS One. 2012;7(1):e29213. doi: 10.1371/journal.pone.0029213.
-
(2012)
PLoS One
, vol.7
, Issue.1
, pp. 29213
-
-
Durfort, T.1
Tkach, M.2
Meschaninova, M.I.3
Rivas, M.A.4
Elizalde, P.V.5
Venyaminova, A.G.6
-
52
-
-
59349116903
-
Knocking down barriers: Advances in siRNA delivery
-
10.1038/nrd2742 19180106 1:CAS:528:DC%2BD1MXhtFOqt70%3D
-
Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129-38. doi: 10.1038/nrd2742.
-
(2009)
Nat Rev Drug Discov
, vol.8
, Issue.2
, pp. 129-138
-
-
Whitehead, K.A.1
Langer, R.2
Anderson, D.G.3
-
53
-
-
67349222877
-
Reversibility and recurrence of IGF-IR-induced mammary tumors
-
10.1038/onc.2009.79 19377512 1:CAS:528:DC%2BD1MXks12kurY%3D
-
Jones RA, Campbell CI, Wood GA, Petrik JJ, Moorehead RA. Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene. 2009;28(21):2152-62. doi: 10.1038/onc.2009.79.
-
(2009)
Oncogene
, vol.28
, Issue.21
, pp. 2152-2162
-
-
Jones, R.A.1
Campbell, C.I.2
Wood, G.A.3
Petrik, J.J.4
Moorehead, R.A.5
-
54
-
-
84861991534
-
MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type i insulin-like growth factor receptor
-
10.1016/j.bcp. 2012.04.017 22580051 1:CAS:528:DC%2BC38XntlWmt7c%3D
-
Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, et al. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol. 2012;84(3):320-30. doi: 10.1016/j.bcp. 2012.04.017.
-
(2012)
Biochem Pharmacol
, vol.84
, Issue.3
, pp. 320-330
-
-
Shen, K.1
Liang, Q.2
Xu, K.3
Cui, D.4
Jiang, L.5
Yin, P.6
-
55
-
-
83555177355
-
MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor
-
10.1136/gutjnl-2011-300178 21813472 1:CAS:528:DC%2BC38XitFWntb0%3D
-
Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut. 2012;61(1):33-42. doi: 10.1136/gutjnl-2011-300178.
-
(2012)
Gut
, vol.61
, Issue.1
, pp. 33-42
-
-
Kong, K.L.1
Kwong, D.L.2
Chan, T.H.3
Law, S.Y.4
Chen, L.5
Li, Y.6
-
56
-
-
0032513524
-
Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R
-
10.1002/(SICI)1097-0215(19980413)76:2<223: AID-IJC9>3.0.CO;2-Z 9537584 1:CAS:528:DyaK1cXitlOlt7c%3D
-
Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer. 1998;76(2):223-7. doi:10.1002/(SICI)1097-0215(19980413)76:2<223::AID- IJC9>3.0.CO;2-Z.
-
(1998)
Int J Cancer
, vol.76
, Issue.2
, pp. 223-227
-
-
Kalebic, T.1
Blakesley, V.2
Slade, C.3
Plasschaert, S.4
Leroith, D.5
Helman, L.J.6
-
57
-
-
79952135852
-
The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells
-
10.1210/me.2010-0373 21292829 1:CAS:528:DC%2BC3MXjvFamtLg%3D
-
Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol. 2011;25(3):516-28. doi: 10.1210/me.2010-0373.
-
(2011)
Mol Endocrinol
, vol.25
, Issue.3
, pp. 516-528
-
-
Becker, M.A.1
Ibrahim, Y.H.2
Cui, X.3
Lee, A.V.4
Yee, D.5
-
58
-
-
84861487778
-
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro
-
22593441 1:CAS:528:DC%2BC38Xoslaqu70%3D
-
Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012;32(5):1627-37.
-
(2012)
Anticancer Res
, vol.32
, Issue.5
, pp. 1627-1637
-
-
Liu, H.1
Scholz, C.2
Zang, C.3
Schefe, J.H.4
Habbel, P.5
Regierer, A.C.6
-
59
-
-
1042267229
-
Determinants of rapamycin sensitivity in breast cancer cells
-
14871980 1:CAS:528:DC%2BD2cXhtFCgurY%3D
-
Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 2004;10(3):1013-23.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.3
, pp. 1013-1023
-
-
Noh, W.C.1
Mondesire, W.H.2
Peng, J.3
Jian, W.4
Zhang, H.5
Dong, J.6
-
60
-
-
79958698108
-
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens
-
10.1158/1535-7163.MCT-10-0792 21482695 1:CAS:528:DC%2BC3MXnt1anurs%3D
-
Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, et al. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011;10(6):1059-71. doi: 10.1158/1535-7163.MCT-10-0792.
-
(2011)
Mol Cancer Ther
, vol.10
, Issue.6
, pp. 1059-1071
-
-
Rivera, V.M.1
Squillace, R.M.2
Miller, D.3
Berk, L.4
Wardwell, S.D.5
Ning, Y.6
-
61
-
-
0034790016
-
MTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
-
Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Canc. 2001;8(3):249-58.
-
(2001)
Endocr Relat Canc
, vol.8
, Issue.3
, pp. 249-258
-
-
Yu, K.1
Toral-Barza, L.2
Discafani, C.3
Zhang, W.G.4
Skotnicki, J.5
Frost, P.6
-
62
-
-
84864558874
-
Randomized Phase II Trial of Everolimus in Combination with Tamoxifen in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors: A GINECO Study
-
doi: 10.1200/JCO.2011.39.0708
-
Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G et al. Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. J Clin Oncol. 2012. doi: 10.1200/JCO.2011.39.0708.
-
(2012)
J Clin Oncol.
-
-
Bachelot, T.1
Bourgier, C.2
Cropet, C.3
Ray-Coquard, I.4
Ferrero, J.M.5
Freyer, G.6
-
63
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
-
10.1056/NEJMoa1109653 22149876 1:CAS:528:DC%2BC38XisVKqsrs%3D
-
Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-9. doi: 10.1056/NEJMoa1109653.
-
(2012)
N Engl J Med
, vol.366
, Issue.6
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
Burris III, H.A.4
Rugo, H.S.5
Sahmoud, T.6
-
64
-
-
3342958797
-
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
-
10.1083/jcb.200403069 15249583 1:CAS:528:DC%2BD2cXlvFKqsrw%3D
-
Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166(2):213-23. doi: 10.1083/jcb.200403069.
-
(2004)
J Cell Biol
, vol.166
, Issue.2
, pp. 213-223
-
-
Harrington, L.S.1
Findlay, G.M.2
Gray, A.3
Tolkacheva, T.4
Wigfield, S.5
Rebholz, H.6
-
65
-
-
27644534999
-
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
-
10.1158/1535-7163.MCT-05-0068 16227402 1:CAS:528:DC%2BD2MXhtFWhtLjE
-
Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005;4(10):1533-40. doi: 10.1158/1535-7163.MCT-05-0068.
-
(2005)
Mol Cancer Ther
, vol.4
, Issue.10
, pp. 1533-1540
-
-
Shi, Y.1
Yan, H.2
Frost, P.3
Gera, J.4
Lichtenstein, A.5
-
66
-
-
0036633164
-
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells
-
12479367 1:CAS:528:DC%2BD38XlsFSmtLk%3D
-
Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002;1(9):707-17.
-
(2002)
Mol Cancer Ther
, vol.1
, Issue.9
, pp. 707-717
-
-
Clark, A.S.1
West, K.2
Streicher, S.3
Dennis, P.A.4
-
67
-
-
84857915302
-
Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth
-
10.1007/s10549-011-1540-0 1:CAS:528:DC%2BC38XitVSksLY%3D
-
Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, et al. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Canc Res Treat. 2012;132(1):61-73. doi: 10.1007/s10549-011-1540-0.
-
(2012)
Breast Canc Res Treat
, vol.132
, Issue.1
, pp. 61-73
-
-
Casa, A.J.1
Potter, A.S.2
Malik, S.3
Lazard, Z.4
Kuiatse, I.5
Kim, H.T.6
-
68
-
-
76049123027
-
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
-
10.1073/pnas.0905152106 20007781 1:CAS:528:DC%2BC3cXmtlagug%3D%3D
-
Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A. 2009;106(52):22299-304. doi: 10.1073/pnas.0905152106.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, Issue.52
, pp. 22299-22304
-
-
Brachmann, S.M.1
Hofmann, I.2
Schnell, C.3
Fritsch, C.4
Wee, S.5
Lane, H.6
-
69
-
-
32944457518
-
MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
10.1158/0008-5472.CAN-05-2925 16452206
-
O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500-8. doi: 10.1158/0008-5472.CAN-05-2925.
-
(2006)
Cancer Res
, vol.66
, Issue.3
, pp. 1500-1508
-
-
O'Reilly, K.E.1
Rojo, F.2
She, Q.B.3
Solit, D.4
Mills, G.B.5
Smith, D.6
-
70
-
-
33947538050
-
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
-
10.1038/sj.onc.1209990 17001314 1:CAS:528:DC%2BD2sXjtlWgtLw%3D
-
Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26(13):1932-40. doi: 10.1038/sj.onc.1209990.
-
(2007)
Oncogene
, vol.26
, Issue.13
, pp. 1932-1940
-
-
Wan, X.1
Harkavy, B.2
Shen, N.3
Grohar, P.4
Helman, L.J.5
-
71
-
-
77956579297
-
A phase i study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors
-
abstr 3008
-
Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, Roda D, Prudkin L, Stein MN et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J Clin Oncol. 2010;28(15):abstr 3008.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.15
-
-
Di Cosimo, S.1
Bendell, J.C.2
Cervantes-Ruiperez, A.3
Roda, D.4
Prudkin, L.5
Stein, M.N.6
-
72
-
-
79957818433
-
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
-
1:CAS:528:DC%2BC38XhtFCjtbk%3D
-
Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Canc Biol Ther. 2011;11(11):938-46.
-
(2011)
Canc Biol Ther
, vol.11
, Issue.11
, pp. 938-946
-
-
Leung, E.1
Kim, J.E.2
Rewcastle, G.W.3
Finlay, G.J.4
Baguley, B.C.5
-
73
-
-
77954746352
-
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
-
10.1158/1078-0432.CCR-09-3022 20606035 1:CAS:528:DC%2BC3cXovVansbk%3D
-
Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 2010;16(14):3628-38. doi: 10.1158/1078-0432.CCR-09-3022.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.14
, pp. 3628-3638
-
-
Cho, D.C.1
Cohen, M.B.2
Panka, D.J.3
Collins, M.4
Ghebremichael, M.5
Atkins, M.B.6
-
74
-
-
0037937417
-
Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells
-
1:CAS:528:DC%2BD3sXmsFCrs7g%3D
-
Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Canc. 2003;10(2):331-45.
-
(2003)
Endocr Relat Canc
, vol.10
, Issue.2
, pp. 331-345
-
-
Hamelers, I.H.1
Steenbergh, P.H.2
-
75
-
-
0031043390
-
Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta
-
9058381 1:CAS:528:DyaK2sXhvVOmsr8%3D
-
Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol. 1997;11(3):353-65.
-
(1997)
Mol Endocrinol
, vol.11
, Issue.3
, pp. 353-365
-
-
Tremblay, G.B.1
Tremblay, A.2
Copeland, N.G.3
Gilbert, D.J.4
Jenkins, N.A.5
Labrie, F.6
-
76
-
-
0035971181
-
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
-
10.1074/jbc.M010840200 11139588 1:CAS:528:DC%2BD3MXis1Olu7k%3D
-
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001;276(13):9817-24. doi: 10.1074/jbc.M010840200.
-
(2001)
J Biol Chem
, vol.276
, Issue.13
, pp. 9817-9824
-
-
Campbell, R.A.1
Bhat-Nakshatri, P.2
Patel, N.M.3
Constantinidou, D.4
Ali, S.5
Nakshatri, H.6
-
77
-
-
0034526749
-
A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor i
-
11108261 1:CAS:528:DC%2BD3cXosVSqsLw%3D
-
Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology. 2000;141(12):4503-11.
-
(2000)
Endocrinology
, vol.141
, Issue.12
, pp. 4503-4511
-
-
Martin, M.B.1
Franke, T.F.2
Stoica, G.E.3
Chambon, P.4
Katzenellenbogen, B.S.5
Stoica, B.A.6
-
78
-
-
0028330135
-
Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells
-
8206329 1:CAS:528:DyaK2cXisVWntbg%3D
-
Lee AV, Darbre P, King RJ. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol. 1994;99(2):211-20.
-
(1994)
Mol Cell Endocrinol
, vol.99
, Issue.2
, pp. 211-220
-
-
Lee, A.V.1
Darbre, P.2
King, R.J.3
-
79
-
-
0033305004
-
Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo
-
10319328 1:CAS:528:DyaK1MXivVyktL0%3D
-
Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999;13(5):787-96.
-
(1999)
Mol Endocrinol
, vol.13
, Issue.5
, pp. 787-796
-
-
Lee, A.V.1
Jackson, J.G.2
Gooch, J.L.3
Hilsenbeck, S.G.4
Coronado-Heinsohn, E.5
Osborne, C.K.6
-
80
-
-
0030067106
-
Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
-
8557625 1:CAS:528:DyaK28XksFOntg%3D%3D
-
Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem. 1996;271(2):1016-21.
-
(1996)
J Biol Chem
, vol.271
, Issue.2
, pp. 1016-1021
-
-
Huynh, H.1
Yang, X.2
Pollak, M.3
-
81
-
-
0026001074
-
Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal proenzymes
-
1656243 1:CAS:528:DyaK3MXks1Gjs7c%3D
-
Mathieu M, Vignon F, Capony F, Rochefort H. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocrinol. 1991;5(6):815-22.
-
(1991)
Mol Endocrinol
, vol.5
, Issue.6
, pp. 815-822
-
-
Mathieu, M.1
Vignon, F.2
Capony, F.3
Rochefort, H.4
-
82
-
-
77950346929
-
Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells
-
10.1016/j.jsbmb.2009.09.018 19815064 1:CAS:528:DC%2BC3cXitlSltLc%3D
-
Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, et al. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol. 2010;118(4-5):219-30. doi: 10.1016/j.jsbmb.2009.09.018.
-
(2010)
J Steroid Biochem Mol Biol
, vol.118
, Issue.4-5
, pp. 219-230
-
-
Song, R.X.1
Chen, Y.2
Zhang, Z.3
Bao, Y.4
Yue, W.5
Wang, J.P.6
-
83
-
-
80052157331
-
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 with Exemestane (E) or Fulvestrant (F) in Postmenopausal Women with Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)
-
Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, De Boer R, Jacot W et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC). Cancer Res. 2010;70(76 s).
-
(2010)
Cancer Res.
, vol.70
, Issue.76
-
-
Kaufman, P.A.1
Ferrero, J.M.2
Bourgeois, H.3
Kennecke, H.4
De Boer, R.5
Jacot, W.6
-
84
-
-
80054921787
-
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment
-
10.1530/ERC-10-0046 1:CAS:528:DC%2BC3MXhsV2ns7jJ
-
Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Canc. 2011;18(5):565-77. doi: 10.1530/ERC-10-0046.
-
(2011)
Endocr Relat Canc
, vol.18
, Issue.5
, pp. 565-577
-
-
Drury, S.C.1
Detre, S.2
Leary, A.3
Salter, J.4
Reis-Filho, J.5
Barbashina, V.6
-
85
-
-
38449108764
-
Molecular mechanisms of erbB2-mediated breast cancer chemoresistance
-
17993237 1:CAS:528:DC%2BC3cXhtlKgsb%2FO
-
Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007;608:119-29.
-
(2007)
Adv Exp Med Biol
, vol.608
, pp. 119-129
-
-
Tan, M.1
Yu, D.2
-
86
-
-
28244432561
-
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
-
10.1158/0008-5472.CAN-04-3841 16322262 1:CAS:528:DC%2BD2MXht1KjsrrI
-
Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65(23):11118-28. doi: 10.1158/0008-5472.CAN-04-3841.
-
(2005)
Cancer Res
, vol.65
, Issue.23
, pp. 11118-11128
-
-
Nahta, R.1
Yuan, L.X.2
Zhang, B.3
Kobayashi, R.4
Esteva, F.J.5
-
87
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
3798106 1:CAS:528:DyaL2sXhtVSht7s%3D
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
-
(1987)
Science
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
88
-
-
0026610881
-
Humanization of an anti-p185HER2 antibody for human cancer therapy
-
1350088 1:CAS:528:DyaK3sXitFSqtb0%3D
-
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285-9.
-
(1992)
Proc Natl Acad Sci U S A
, vol.89
, Issue.10
, pp. 4285-4289
-
-
Carter, P.1
Presta, L.2
Gorman, C.M.3
Ridgway, J.B.4
Henner, D.5
Wong, W.L.6
-
89
-
-
0036534121
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
-
11919237 1:CAS:528:DC%2BD38XjtFGqsrw%3D
-
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800-8.
-
(2002)
J Clin Oncol
, vol.20
, Issue.7
, pp. 1800-1808
-
-
Esteva, F.J.1
Valero, V.2
Booser, D.3
Guerra, L.T.4
Murray, J.L.5
Pusztai, L.6
-
90
-
-
0035915283
-
Unraveling resistance to trastuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect
-
1:STN:280:DC%2BD38%2FgtlKrtA%3D%3D
-
Albanell J, Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Canc Inst. 2001;93(24):1830-2.
-
(2001)
J Natl Canc Inst
, vol.93
, Issue.24
, pp. 1830-1832
-
-
Albanell, J.1
Baselga, J.2
-
91
-
-
78650372147
-
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
-
10.1093/annonc/mdq349 20647220 1:STN:280:DC%2BC3M%2FkvFKksA%3D%3D
-
Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol. 2011;22(1):68-73. doi: 10.1093/annonc/mdq349.
-
(2011)
Ann Oncol
, vol.22
, Issue.1
, pp. 68-73
-
-
Browne, B.C.1
Crown, J.2
Venkatesan, N.3
Duffy, M.J.4
Clynes, M.5
Slamon, D.6
-
92
-
-
51049095723
-
Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer
-
10.1158/1535-7163.MCT-08-0012 18645000 1:CAS:528:DC%2BD1cXoslCgtbs%3D
-
Rowe DL, Ozbay T, Bender LM, Nahta R. Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol Cancer Ther. 2008;7(7):1900-8. doi: 10.1158/1535-7163.MCT-08-0012.
-
(2008)
Mol Cancer Ther
, vol.7
, Issue.7
, pp. 1900-1908
-
-
Rowe, D.L.1
Ozbay, T.2
Bender, L.M.3
Nahta, R.4
-
93
-
-
84860339842
-
Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type i IGF receptor
-
10.1007/s10549-011-1713-x 1:CAS:528:DC%2BC38XmtlOlu7w%3D
-
Zeng X, Zhang H, Oh A, Zhang Y, Yee D. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Canc Res Treat. 2012;133(1):117-26. doi: 10.1007/s10549-011-1713-x.
-
(2012)
Breast Canc Res Treat
, vol.133
, Issue.1
, pp. 117-126
-
-
Zeng, X.1
Zhang, H.2
Oh, A.3
Zhang, Y.4
Yee, D.5
-
94
-
-
1842866389
-
A prospective study of plasma C-peptide and colorectal cancer risk in men
-
1:CAS:528:DC%2BD2cXjtVShtbw%3D
-
Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Canc Inst. 2004;96(7):546-53.
-
(2004)
J Natl Canc Inst
, vol.96
, Issue.7
, pp. 546-553
-
-
Ma, J.1
Giovannucci, E.2
Pollak, M.3
Leavitt, A.4
Tao, Y.5
Gaziano, J.M.6
-
95
-
-
33344467985
-
Targeting insulin-like growth factor pathways
-
10.1038/sj.bjc.6602963 16450000 1:CAS:528:DC%2BD28Xhs1ersrc%3D
-
Yee D. Targeting insulin-like growth factor pathways. Br J Cancer. 2006;94(4):465-8. doi: 10.1038/sj.bjc.6602963.
-
(2006)
Br J Cancer
, vol.94
, Issue.4
, pp. 465-468
-
-
Yee, D.1
-
96
-
-
79956340194
-
Targeting IGF-1R: At a crossroad
-
discussion 51
-
Lee AV, Yee D. Targeting IGF-1R: at a crossroad. Oncol (Williston Park). 2011;25(6):535-6. discussion 51.
-
(2011)
Oncol (Williston Park)
, vol.25
, Issue.6
, pp. 535-536
-
-
Lee, A.V.1
Yee, D.2
-
97
-
-
67650652432
-
I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
-
10.1038/clpt.2009.68 19440188 1:STN:280:DC%2BD1Mvis1Gjsg%3D%3D
-
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100. doi: 10.1038/clpt.2009.68.
-
(2009)
Clin Pharmacol Ther
, vol.86
, Issue.1
, pp. 97-100
-
-
Barker, A.D.1
Sigman, C.C.2
Kelloff, G.J.3
Hylton, N.M.4
Berry, D.A.5
Esserman, L.J.6
-
98
-
-
84863601677
-
Metformin reduces endogenous reactive oxygen species and associated DNA damage
-
10.1158/1940-6207.CAPR-11-0536 1:CAS:528:DC%2BC38XntFOns7c%3D
-
Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli L, Birman E, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Canc Prev Res (Phila). 2012;5(4):536-43. doi: 10.1158/1940-6207. CAPR-11-0536.
-
(2012)
Canc Prev Res (Phila)
, vol.5
, Issue.4
, pp. 536-543
-
-
Algire, C.1
Moiseeva, O.2
Deschenes-Simard, X.3
Amrein, L.4
Petruccelli, L.5
Birman, E.6
-
99
-
-
79954575067
-
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy
-
10.1158/1078-0432.CCR-10-1903 21177763 1:CAS:528:DC%2BC3MXkslCgsbc%3D
-
Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011;17(8):2314-27. doi: 10.1158/1078-0432.CCR-10-1903.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.8
, pp. 2314-2327
-
-
Litzenburger, B.C.1
Creighton, C.J.2
Tsimelzon, A.3
Chan, B.T.4
Hilsenbeck, S.G.5
Wang, T.6
-
100
-
-
58249101005
-
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors
-
10.1158/0008-5472.CAN-08-0835 19117999 1:CAS:528:DC%2BD1MXmvFCi
-
Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009;69(1):161-70. doi: 10.1158/0008-5472.CAN-08-0835.
-
(2009)
Cancer Res
, vol.69
, Issue.1
, pp. 161-170
-
-
Huang, F.1
Greer, A.2
Hurlburt, W.3
Han, X.4
Hafezi, R.5
Wittenberg, G.M.6
-
101
-
-
77953704937
-
Development of an integrated genomic classifier for a novel agent in colorectal cancer: Approach to individualized therapy in early development
-
10.1158/1078-0432.CCR-09-3191 20530704 1:CAS:528:DC%2BC3cXntlKru7Y%3D
-
Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, et al. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res. 2010;16(12):3193-204. doi: 10.1158/1078-0432.CCR-09-3191.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.12
, pp. 3193-3204
-
-
Pitts, T.M.1
Tan, A.C.2
Kulikowski, G.N.3
Tentler, J.J.4
Brown, A.M.5
Flanigan, S.A.6
-
102
-
-
20944440088
-
Tumor development by transgenic expression of a constitutively active insulin-like growth factor i receptor
-
15867374 1:CAS:528:DC%2BD2MXjslGksrg%3D
-
Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 2005;65(9):3781-7.
-
(2005)
Cancer Res
, vol.65
, Issue.9
, pp. 3781-3787
-
-
Carboni, J.M.1
Lee, A.V.2
Hadsell, D.L.3
Rowley, B.R.4
Lee, F.Y.5
Bol, D.K.6
-
103
-
-
0034951677
-
Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion
-
10.1128/MCB.21.15.5082-5093.2001 11438664 1:CAS:528:DC%2BD3MXlsVGitLs%3D
-
Shaw LM. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol Cell Biol. 2001;21(15):5082-93. doi: 10.1128/MCB.21.15.5082-5093.2001.
-
(2001)
Mol Cell Biol
, vol.21
, Issue.15
, pp. 5082-5093
-
-
Shaw, L.M.1
-
104
-
-
0035504405
-
Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines
-
10.1038/sj.onc.1204920 11704861 1:CAS:528:DC%2BD3MXovVOntL0%3D
-
Jackson JG, Zhang X, Yoneda T, Yee D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene. 2001;20(50):7318-25. doi: 10.1038/sj.onc.1204920.
-
(2001)
Oncogene
, vol.20
, Issue.50
, pp. 7318-7325
-
-
Jackson, J.G.1
Zhang, X.2
Yoneda, T.3
Yee, D.4
-
105
-
-
0032540288
-
Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells
-
9545345 1:CAS:528:DyaK1cXivVOrsLs%3D
-
Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J Biol Chem. 1998;273(16):9994-10003.
-
(1998)
J Biol Chem
, vol.273
, Issue.16
, pp. 9994-10003
-
-
Jackson, J.G.1
White, M.F.2
Yee, D.3
-
106
-
-
33750453743
-
Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells
-
10.1038/sj.bjc.6603354 17043687 1:CAS:528:DC%2BD28XhtFChs7zN
-
Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer. 2006;95(9):1220-8. doi: 10.1038/sj.bjc.6603354.
-
(2006)
Br J Cancer
, vol.95
, Issue.9
, pp. 1220-1228
-
-
Byron, S.A.1
Horwitz, K.B.2
Richer, J.K.3
Lange, C.A.4
Zhang, X.5
Yee, D.6
-
107
-
-
78650858388
-
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
-
10.1038/sj.bjc.6605972 21102589 1:CAS:528:DC%2BC3MXhs1eksg%3D%3D
-
Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer. 2011;104(1):68-74. doi: 10.1038/sj.bjc.6605972.
-
(2011)
Br J Cancer
, vol.104
, Issue.1
, pp. 68-74
-
-
Gualberto, A.1
Hixon, M.L.2
Karp, D.D.3
Li, D.4
Green, S.5
Dolled-Filhart, M.6
-
108
-
-
84867574623
-
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas
-
doi: 10.1016/j.ejca.2012.05.009
-
Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer. 2012. doi: 10.1016/j.ejca.2012.05.009.
-
(2012)
Eur J Cancer.
-
-
Asmane, I.1
Watkin, E.2
Alberti, L.3
Duc, A.4
Marec-Berard, P.5
Ray-Coquard, I.6
-
109
-
-
84858208702
-
IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors
-
10.1158/1078-0432.CCR-11-1806 22287600 1:CAS:528:DC%2BC38XktVyms70%3D
-
Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, et al. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res. 2012;18(6):1808-17. doi: 10.1158/1078-0432.CCR-11-1806.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.6
, pp. 1808-1817
-
-
Becker, M.A.1
Hou, X.2
Harrington, S.C.3
Weroha, S.J.4
Gonzalez, S.E.5
Jacob, K.A.6
|